delavirdine + indinavir + lamivudine

Delavirdine + indinavir + lamivudine is an oral fixed-dose combination regimen composed of three antiretroviral drugs: **delavirdine** (a non-nucleoside reverse transcriptase inhibitor), **indinavir** (an HIV protease inhibitor), and **lamivudine** (a nucleoside reverse transcriptase inhibitor). This **triple combination therapy** acts on multiple steps in the HIV replication cycle, targeting reverse transcriptase and protease enzymes, and is used primarily in the treatment of HIV-1 infection. The combination has been shown to result in potent and durable suppression of plasma HIV-1 RNA and sustained increases in CD4 cell counts. Clinical experience indicates the regimen is well tolerated and effective, particularly in patients with prior treatment failure on protease inhibitor regimens[3][4].